Monoclonal Antibody Development Targeting TNFα for Autoimmune Diseases

As a leader and expert in the field of drug development for autoimmune diseases, Creative Biolabs provides state-of-the-art technologies to meet any requirement of our customers. We have completed a series of challenges in the past years. In particular, we have established a monoclonal antibody development targeting tumor necrosis factor-alpha (TNFα) discovery platform which enables us to offer a series of high-quality services for treating many autoimmune diseases.

Introduction to TNFα Functions in Autoimmune Diseases

TNFα is a type of pro-inflammatory cytokine that is associated with a wide variety of autoimmune diseases, such as systemic lupus erythematosus (SLE), plaque psoriasis (PP), and rheumatoid arthritis (RA). Meanwhile, pilot studies have demonstrated that TNFα also plays an important role in regulating immune responses and immune homeostasis. In general, TNFα can be produced by a range of cell types, including T cells, natural killer (NK) cells, macrophages, as well as neutrophils.

Till now, two main types of TNFα receptors, TNFR1 and TNFR2, have been identified that are involved in many biological activities. For instance, the deficiency of TNFR1 in lupus models can lead to many adverse immune reactions. Also, TNFR2 can cause leukocyte infiltration and tissue damage in animal models of immune-mediated glomerulonephritis. As a result, a full range of therapies targeting TNFα has been generated for improving the clinical outcomes of autoimmune diseases. All of these drugs, especially for monoclonal antibody agents, are designed based on blocking TNF transcription, inhibiting TNFα activity, and preventing TNF-mediated signaling pathways.

TNF signaling though TNFR1 and TNFR2 in normal T cells compared to abnormal (autoimmune) T cells.Fig.1 TNF signaling though TNFR1 and TNFR2 in normal T cells compared to abnormal (autoimmune) T cells. (Faustman, 2010)

Monoclonal Antibody Development Targeting TNFα for Autoimmune Diseases

Currently, TNFα has been regarded as one of the most essential inflammatory cytokines and has been broadly studied in autoimmune disease therapies. Nowadays, neutralizing TNFα or antagonizing the function of TNFR1 and TNFR2 has become common strategies for the treatment of autoimmune diseases.

To achieve the success of such a strategy, Creative Biolabs has established a well-mature antibody discovery platform to offer a complete monoclonal antibody development targeting the TNFα service chain, ranging from target identification, antibody production, and antibody preclinical development to antibody evaluation. Our platform is equipped with advanced facilities and highly experienced staff are available to assist in all areas of TNFα-based monoclonal antibody development projects. In the past few years, we have successfully designed several monoclonal antibodies against TNFα or its receptors to treating patients with RA, psoriasis, and colitis in the clinic. The data have suggested that these fully human, humanized, or chimeric antibodies are effective in the treatment of autoimmune diseases associated with the overproduction of TNFα.

Besides, we also provide a panel of antibody characterization services, such as binding affinity assays, solubility testing, and pharmacokinetics assessment. Parameters of monoclonal antibodies targeting TNFα can be further optimized by using our numerous databases to improve their safety and efficacy in clinical applications.

Why Creative Biolabs?

In addition to providing information on target identification, antibody selection, and the most important inflammatory cytokines studies, Creative Biolabs can also tailor our services to the specific requirements of our customers. If you have already performed a part of the antibody development procedures in your lab, we can also integrate comprehensive pre-clinical studies into your workflow.

  • Precise target identification and validation
  • Multiple TNFα-based research databases
  • Professional knowledge of antibody discovery
  • Integrated solution based on various technologies

By continuing to grow in response to the requirements of our clients, Creative Biolabs is dedicated to exploring novel and innovative TNFα-based antibody development strategies to offer the most comprehensive, integrated portfolio of antibody discovery products and solutions. If you are interested in our services, please contact us for more details. Let us know what you need and we will accommodate you. We look forward to working with you in the future.


  1. Faustman, D.; et al. TNF receptor 2 pathway: drug target for autoimmune diseases. Nature reviews Drug discovery. 2010, 9(6): 482-493.

For Research Use Only | Not For Clinical Use

Online Inquiry


We are dedicated to advancing and facilitating your drug development against autoimmune diseases

Contact us


  • Location:

  • Call:

  • Fax:

  • Email:


  • Location:

  • Call:

  • Email:

Autoimmune Diseases,Drug Development for
Autoimmune Diseases

Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.

Copyright © 2023 Creative Biolabs. All Rights Reserved.